MedTrace Logo

Valuation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) in Patients Affected by Primary Open Angle Glaucoma

NCT04038034 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2020-04-28

No results posted yet for this study

Summary

This is a randomized, double blind study with competitive enrolment, aimed to enroll a total of 70 patients with a diagnosis of primary open angle glaucoma (POAG).

Patients, after signing the Informed Consent, will enter into a 1- week screening phase during which the baseline tests will be conducted.

Subjects will be randomized in a 1:1 ratio to the following groups:

* group A of 35 patients treated with pressure lowering drugs and placebo;
* group B of 35 patients with pressure lowering drugs and COQUN oral formulation 100 mg BID.

Conditions

  • Glaucoma, Open-Angle

Interventions

DIETARY_SUPPLEMENT

CoQ10- MINIACTIVES

COQUN oral formulation 100 mg BID

DIETARY_SUPPLEMENT

Placebo

Placebo

Sponsors & Collaborators

  • VISUfarma SpA

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2021-08-30
Completion
2021-08-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04038034 on ClinicalTrials.gov